Disease Markers / 2016 / Article / Tab 3

Research Article

Effects of Ramipril and Telmisartan on Plasma Concentrations of Low Molecular Weight and Protein Thiols and Carotid Intima Media Thickness in Patients with Chronic Kidney Disease

Table 3

Drug effects on LMW thiols.

Group 1 ()Group 2 ()
BaselineTelmisartan/ramipril
40/5 mg/day
p valueBaselineTelmisartan
80 mg/day
p value
Mean ± SD
or
median (IQR)
Mean ± SD
or
median (IQR)
Mean ± SD
or
median (IQR)
Mean ± SD
or
median (IQR)

Total LMW thiols
 t-CysGly, µmol/L31.6 ± 8.831.1 ± 8.50.8928.8 ± 8.425.6 ± 7.90.35
 t-Hcy, µmol/L16.3 (12.1–26.3)17.3 (10.3–27.6)0.9019.2 (11.8–23.7)14.4 (11.2–19.2)0.27
 t-Cys, µmol/L391 ± 89404 ± 1220.77370 ± 109341 ± 940.49
 t-GSH, µmol/L7.4 ± 2.17.7 ± 1.80.717.6 ± 3.27.6 ± 4.61.00
 t-GluCys, µmol/L5.7 (4.5–6.0)5.7 (4.4–9.7)0.385.4 (3.5–7.6)4.4 (3.2–7.2)0.95
 Sum of total LMW thiols, µmol/L458 ± 106472 ± 1440.79432 ± 122400 ± 1120.51
Reduced LMW thiols
 r-CysGly, µmol/L5.8 ± 1.65.5 ± 1.60.656.6 ± 2.66.4 ± 1.70.83
 r-Hcy, µmol/L0.20 (0.13–0.37)0.17 (0.12–0.36)0.570.29 (0.18–0.37)0.23 (0.17–0.29)0.42
 r-Cys, µmol/L20.9 ± 4.719.7 ± 4.70.5421.9 ± 3.521.0 ± 4.40.58
 r-GSH, µmol/L1.01 (0.74–1.31)0.94 (0.47–1.37)0.911.11 (0.85–1.67)1.10 (0.71–1.60)0.34
 r-GluCys, µmol/L0.35 (0.22–0.58)0.41 (0.31–0.47)0.850.37 (0.27–0.44)0.43 (0.33–0.45)0.97
 Sum of reduced sLMW thiols, µmol/L28.4 ± 5.926.1 ± 5.10.3230.5 ± 6.029.3 ± 5.80.62
Thiols redox status
 LMW redox, %0.066 ± 0.0230.061 ± 0.0250.620.078 ± 0.0300.079 ± 0.0280.93